<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04492956</url>
  </required_header>
  <id_info>
    <org_study_id>EBS-101-COFD-201</org_study_id>
    <nct_id>NCT04492956</nct_id>
  </id_info>
  <brief_title>Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Exploratory Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Adults With Childhood Onset Fluency Disorder (Stuttering)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emalex Biosciences Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, Riverside</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Emalex Biosciences Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2&#xD;
      exploratory study in adult subjects with childhood onset fluency disorder.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the Baseline visit, eligible subjects will be randomized 1:1 to receive either a target&#xD;
      steady-state dose of ecopipam HCl ~2 mg/kg/day or matching placebo for a 12-week Treatment&#xD;
      Period consisting of a 4-week Titration Phase followed by an 8-week Maintenance Phase.&#xD;
&#xD;
      Subjects will return to the clinic at 4, 8, and 12 weeks after Randomization and Follow-up&#xD;
      visits 7 and 14 days after completing the Treatment Period or Early Discontinuation. Efficacy&#xD;
      assessments will be conducted at Weeks 4, 8, and 12 and safety assessments will be conducted&#xD;
      at all visits. Subjects will have adverse events and other safety parameters assessed by&#xD;
      phone or video conference at Weeks 2, 6 and 10 and 30 days after the last study drug&#xD;
      administration. Signs or symptoms of withdrawal, abuse, and dependence will be monitored&#xD;
      throughout the study.&#xD;
&#xD;
      At the end of the Treatment Period or Early Discontinuation, subjects will taper study drug&#xD;
      by 25 mg/day until off study drug, for up to 1 week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Stuttering Severity Instrument, 4th edition (SSI-4) baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Measures stuttering severity in children and adults</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity (CGI-S) baseline to Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rates the severity of the subject's illness at the time of assessment, relative to the the clinician's past experience with patients who have the same diagnosis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Childhood-Onset Fluency Disorder (Stuttering)</condition>
  <arm_group>
    <arm_group_label>Ecopipam HCl ~2mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo tablets for daily, oral administration for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ecopipam</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Ecopipam HCl ~2mg/kg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to read and write in English and provide informed consent&#xD;
&#xD;
          -  18 years or older of age at screening&#xD;
&#xD;
          -  Weighs &gt;= 45 kg (~99 lbs)&#xD;
&#xD;
          -  Satisfies DSM-5 criteria for childhood onset fluency disorder&#xD;
&#xD;
          -  History of stuttering for &gt;=2 years with onset consistent to developmental in nature&#xD;
&#xD;
          -  Must meet an allowed severity of stuttering at screening and baseline, scored by a&#xD;
             central rater&#xD;
&#xD;
          -  Completed an adequate course of speech therapy&#xD;
&#xD;
          -  Has a qualifying IOS or Android smartphone&#xD;
&#xD;
          -  Must discontinue all medications used to treat stuttering for at least 14 days prior&#xD;
             to screening&#xD;
&#xD;
          -  Sexually active females of child bearing potential must be using effective&#xD;
             contraception during and 30 days after participation&#xD;
&#xD;
          -  Sexually active males must use a double barrier method of contraception during and 30&#xD;
             days after participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stuttering is related to a known neurological cause&#xD;
&#xD;
          -  Initiation of new behavioral therapies for stuttering within 10 weeks prior to&#xD;
             baseline&#xD;
&#xD;
          -  Unstable medical illness or clinically significant abnormalities on screening&#xD;
             tests/exams&#xD;
&#xD;
          -  At a significant risk of committing suicide&#xD;
&#xD;
          -  Are pregnant or lactating&#xD;
&#xD;
          -  Positive urine drug screen&#xD;
&#xD;
          -  Lifetime history of major depressive episode&#xD;
&#xD;
          -  History of seizures&#xD;
&#xD;
          -  Have been previously treated with ecopipam&#xD;
&#xD;
          -  Unstable use of medications prior to screening&#xD;
&#xD;
          -  Use of prohibited medications or need for medications which would have unfavorable&#xD;
             interactions with ecopipam&#xD;
&#xD;
          -  Not suitable for study in the opinion of the Principle Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Atul R Mahableshwarkar, MD, DFAPA</last_name>
    <role>Study Director</role>
    <affiliation>Emalex Biosciences Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kerensa Saljooqi</last_name>
    <phone>415-656-7149</phone>
    <email>ksaljooqi@emalexbiosciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Riverside</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CI Trials</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tommy Gonzalez</last_name>
      <phone>714-912-2499</phone>
      <email>bestutterfree@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert Bota, MD,MSG, DFAPA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute For Advanced Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Social Psychiatry Research Institute</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Social Psychiatry Research Institute</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions Inc</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stuttering</keyword>
  <keyword>Communication Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stuttering</mesh_term>
    <mesh_term>Childhood-Onset Fluency Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ecopipam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

